Download the appMore options
PisaczekSearch
文AEN
Public health and WHO

An Expensive Prescription Drug? The Truth About Conferences Funded by Companies!

Sources: 18 · Article: 22 308 characters ↓

What do Natural Therapy Specialists write?

Jerzy Zięba

Pharmaceutical companies fund conferences where lectures about new drugs predominate, rather than lectures about new treatment methods.

„Unfortunately, in Poland doctors are not required to diligently expand their knowledge, and training conferences are dominated by lectures about new drugs rather than innovative ways of restoring health. Well, pharmaceutical companies, the sponsors of these conferences, are mainly interested in promoting new drugs, not new knowledge.”Niestety w Polsce lekarz nie ma obowiązku sumiennego poszerzania wiedzy, a na zjazdach szkoleniowych dominują wykłady o nowych lekach, a nie nowatorskich metodach przywracania zdrowia. No cóż – firmom farmaceutycznym, fundatorom zjazdów, chodzi głównie o popularyzację nowych leków, a nie nowej wiedzy.
Jerzy Zięba

Medical schools are said to depend on money from pharmaceutical companies, which, according to the author, makes it difficult to use methods outside the industry.

„Medical schools completely ignore these forms of treatment. They depend on funding that they receive from pharmaceutical companies in all sorts of ways; they are at their mercy, and woe to anyone who “breaks ranks” and starts using something that is not produced by the pharmaceutical industry.”uczelnie medyczne ignorują całkowicie te formy leczenia. Uzależnione są od funduszy, jakie w najprzeróżniejszych formach otrzymują z firm farmaceutycznych, są na ich łasce i biada temu, kto się „wyłamie” i zacznie stosować coś, co nie jest produkowane przez przemysł farmaceutyczny.
Andrzej Frydrychowski

The author calls doctors who act at the pharmaceutical industry's direction its sales agents.

„They are, in fact and in law, sales agents for pharmaceutical and medical companies. A doctor who acts at the direction of the medical industry, pharmaceutical companies, and medical chambers ceases to be a doctor and becomes a primitive—a medical assistant (with no disrespect to medical assistants, who do practically good work).”Są de facto i de iure akwizytorami handlowymi firm farmaceutycznych i medycznych. Lekarz, który działa pod dyktando przemysłu medycznego, firm farmaceutycznych i Izb Lekarskich przestaje być lekarzem, a zaczyna być prymitywem – felczerem (nie ubliżając felczerom, którzy robią praktycznie dobrą robotę).
Andrzej Frydrychowski

The author claims that doctors are made to choose between independent treatment and following orders linked to the interests of industry.

„Having acquired the latest, most cutting-edge knowledge, they must face this dilemma: Should they be ethical and honest doctors, putting the latest advances and achievements in medicine, especially medical science, into practice, or should they follow the orders of medical chambers, which obey the government and are subordinate to the interests of big industry?”Zdobywszy zaś najnowszą, najbardziej awangardową wiedzę, musi stanąć przed takim oto dylematem: Być etycznym i prawym lekarzem, wdrażając do leczenia najnowsze zdobycze i osiągnięcia medycyny, w tym głównie nauk medycznych, czy też wykonywać polecenia Izb lekarskich, posłusznych rządowi i podporządkowanych interesom wielkiego przemysłu.
Andrzej Frydrychowski

The author claims that, in exchange for banning effective methods, doctors are instructed to use expensive drugs with little effectiveness.

„As if that were not enough, doctors lose their right to practice for using effective treatment methods. Instead, they are instructed to use drugs that are not very effective but very expensive, and that cause complications and numerous side effects, such as statins.”Jakby tego było mało, za stosowanie skutecznych metod leczenia odbiera się lekarzom prawo wykonywania zawodu. W zamian nakazuje się stosowanie mało skutecznych, ale bardzo drogich leków, skutkujących powikłaniami i licznymi objawami ubocznymi np. statyn.
Stowarzyszenie STOP NOP

The STOP NOP Association says that industry influences, among other things, the training of health care workers and medical practice.

„Results: We presented extensive, consistent evidence showing that industry has created means of intervention at every stage of the processes that shape medical research, policy, funding, health care practice, and education.”Wyniki: Przedstawiliśmy wiele spójnych dowodów wykazujących fakt utworzenia przez przemysł środków interwencji na wszystkich etapach procesów decydujących w zakresie badań medycznych, strategii, nakładów, praktyki i edukacji w zakresie ochrony zdrowia.
Stowarzyszenie STOP NOP

According to the STOP NOP Association, industry interference may exaggerate the benefits of drugs, downplay their possible harms, and influence practice and guidelines.

„As a result of this interference, the benefits of using drugs and other products are often exaggerated in relation to their possible harms, which are played down, while clinical guidelines, medical practice, and health care funding are shaped by biased decisions.”W wyniku tych ingerencji, korzyści stosowania leków i innych produktów często są wyolbrzymiane w stosunku do możliwej szkodliwości, którą się bagatelizuje, a wytyczne kliniczne, praktyka medyczna i nakłady na opiekę zdrowotną są realizowane w oparciu o stronnicze decyzje.
Stowarzyszenie STOP NOP

The STOP NOP Association writes that industry directly influences decisions made by health care workers.

„Conclusion: To serve its own interests, the medical industry skillfully influences the production of evidence, the synthesis of evidence, the understanding of harms, the assessment of costs, clinical guidelines, and training for health care workers. It also directly influences decisions made by health care workers and patients.”Wniosek By móc służyć swoim interesom, przemysł medyczny mistrzowsko wpływa na produkcję podstaw dowodowych, syntezę dowodów, rozumienie kwestii szkodliwości, szacunek kosztów, wytyczne kliniczne i szkolenia dla pracowników służby zdrowia, jak również wywiera bezpośredni wpływ na decyzje podejmowane przez pracowników i klientów opieki zdrowotnej.
Jerzy Jaśkowski

Jerzy Jaśkowski claims that doctors have been manipulated into selling harmful products while believing that they are helping patients.

„In a single generation, more than 100,000 doctors have been so misled that they are involved in selling harmful products, believing that they are helping people. And all this trade is overseen by the Ministry called Health. The Canadian Network for Observational Drug Effect Studies (CNODES) published a report clearly indicating a link between kidney failure and taking statins.”W ciągu jednego pokolenia udało się ponad 100 000 lekarzy tak otumanić, że zajmują sie handlem szkodliwymi preparatami wierząc, że pomagają ludziom. A nad całym tym handlem czuwa Ministerstwo zwane Zdrowia. Kanadyjska sieć Badań Obserwacyjnych Działań Leków CNODES opublikowała raport wskazujący jednoznacznie na istnienie związku niewydolności nerek z przyjmowaniem statyn.
Jerzy Jaśkowski

Jerzy Jaśkowski accuses cardiologists of providing the pharmaceutical industry with chronically ill patients.

„It can be observed that cardiologists “produce” more and more chronically ill patients, lining the pockets of the pharmaceutical industry. A 2015 study by the University of Texas found that diabetes incidence increased by as much as 87% among patients receiving statins.”Można zauważyć, że kardiolodzy „produkują” kolejnych przewlekle chorych, nabijając kasę przemysłowi farmaceutycznemu. Badania przeprowadzone przez Uniwersytet w Teksasie w 2015 roku wykazały, że aż o 87% zwiększyło się zachorowanie na cukrzycę o pacjentów otrzymujących statyny.

What does scientific research from PubMed · Europe PMC say?

We selected 10 studies with the best, positive results. This is a selection, not a full review of all research.

Total number of studies on this topic in PubMed: 4 108.

Aim of the study: Controversy exists over the fact that physicians have regular contact with the pharmaceutical industry and its sales representatives, who spend a large sum of money each year promoting to them by way of gifts, free meals, travel subsidies, sponsored teachings, and symposia.

Results: The present extent of physician-industry interactions appears to affect prescribing and professional behavior and should be further addressed at the level of policy and education.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studycombined analysis of many studies (meta-analysis)

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Pharmaceutical companies spend large amounts of money promoting their products to physicians. There is evidence that physicians' interactions with pharmaceutical companies negatively affect their prescribing patterns. The objective of this study was to systematically review the extent of the relationship between physicians and pharmaceutical companies in low- and middle-income countries (LMICs).

Results: We included 11 eligible studies (7 quantitative and 4 qualitative). Quantitative studies found that pharmaceutical company representatives visited at least 90% of physicians. Printed material, stationery items and drug samples were the most frequently received gifts. Two of the studies assessing direct payment found percentages of 16 and 5%, respectively. Findings of qualitative studies were consistent with those of quantitative studies. In addition, they revealed an increasing tendency for pharmaceutical companies to provide expensive personal gifts, sponsor social events and offer cash as inducements to physicians based on their demands. They also identified building personal relationships, creating a sense of indebtedness and emotional blackmailing as commonly used techniques to influence physicians. A relatively high percentage of physicians in LMICs interact with pharmaceutical companies.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studyreview of many studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: To evaluate the association between industry payments to physicians related to poly (ADP-ribose) polymerase inhibitors (PARPis) and physicians' prescribing behaviors for PARPis.

Results: Of the 1686 eligible physician prescribers, 68.7% received one or more non-research payments related to any of the three PARPis from the manufacturers between 2017 and 2021. Median annual payments per physician were $57 for olaparib, $39 for rucaparib, and $62 for niraparib. Receipt of payments for each PARPi was associated with higher odds of prescribing olaparib (odds ratio [OR]: 1.30 [95% CI: 1.14-1.48], p < 0.001), rucaparib (OR: 2.07 [95% CI: 1.58-2.72], p < 0.001), and niraparib (OR: 1.49 [95% CI: 1.22-1.81], p < 0.001). Dose-response effects were observed between the number of annual payments and the number of prescriptions and/or Medicare expenditures for olaparib and rucaparib. Non-research payments to physician prescribers of PARP inhibitors from the manufacturers were significantly associated with increased prescriptions and Medicare expenditures for olaparib and rucaparib in the United States.

Money for the studycompany together with others · Tohoku University, NIH HHS, National Institutes of Health
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?YES
Type of studyobservation of people
Participants1 686

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: The pharmaceutical industry spends billions of dollars every year for marketing its products to US health care providers. This study investigates the association between industry marketing payments and physicians' prescription in New York and Massachusetts, and examines the effect of the Massachusetts payment restriction policy on this association in comparison with the New York State that has no payment restriction policy.

Results: Moreover, FE and FD models show that compared to NYS physicians, the association of industry payments with days' supply and costs of Medicare Part D prescriptions was (0.01%-0.02%) smaller for MA physicians. Because of the smaller sample size and lower power, the LFD model did not detect a significant difference between the NYS and MA providers. The findings of this study provide additional evidence that industry payments are associated with increases in the volume and cost of Medicare prescriptions. Moreover, these findings provide preliminary evidence that payment restriction policies negatively moderate this association, which calls for further research.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studyobservation of people

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Payments to physicians by the pharmaceutical industry are common, but recent evidence shows that these payments influence physician prescribing behavior in the form of increased prescription of brand-name drugs, expensive and low-cost drugs, increased prescription of payer company drugs, etc. Considering that these payments increase drug costs for patients and health systems, there is a public interest in controlling them.

Results: In the search, 579 articles were retrieved, and 44 articles were found suitable for the final analysis. Twenty-nine interventions and strategies were identified, and based on these; Five policy options were identified: prohibition, restriction, physician self-regulation, voluntary industry disclosure, and mandatory industry disclosure. The proposed policies in our study include advantages, challenges, and implementation considerations based on up-to-date evidence that can help policymakers use them to manage COI in physician-pharmaceutical industry interactions in Iran's health system. A combination of measures seems to help manage COI: firstly, using self-regulating physicians and industry to institutionalize transparency, and in the next step, implementing mandatory industry disclosure policies and establishing restrictions on some financial interactions.

Money for the studynot stated
Do the authors have ties to companies?yes — the authors reported it
Did a manufacturer help with the study?YES
Type of studyreview of many studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Due to sanitary restrictions secondary to the COVID-19 pandemic, various interactions between the pharmaceutical industry and physicians have changed. One of them has been the method for promoting medicinal products through academic meetings around diseases of financial interest.

Results: One of them has been the method for promoting medicinal products through academic meetings around diseases of financial interest. A recent modality has been unilateral promotion by the pharmaceutical industry through academic events with the invitation of so-called "experts" for the promotion of a specific drug. These meetings are often biased not towards optimal care of a disease, but rather towards commercial promotion of a specific drug, which may or may not be the best option, without considering associated therapeutic alternatives. The Committee of Ethics and Transparency in the Physician-Industry Relationship, of the National Academy of Medicine, analyzes this new circumstance and proposes some considerations to the medical community.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studyother

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: The Centers for Medicare & Medicaid Services (CMS) Open Payments public database, resulting from the Physician Payments Sunshine Act of 2010, was designed to increase transparency of physicians' financial relationships with pharmaceutical manufacturers. We compared physician-reported conflict-of-interest (COI) disclosures in journal articles with this database to determine any discrepancies in physician-reported disclosures.

Results: We reviewed 3,465 authorship positions (1,932 unique authors) in 1,770 articles. Within this sample, 7.1% of authorships had a recorded undisclosed COI (disclosure discrepancy), and 13.2% of articles had first and/or last authors with a disclosure discrepancy. Additionally, we saw a great variation in the percentage of authorships with disclosure discrepancies among the journals (JBJS, 2.3%; JOA, 3.6%; and FAI, 23.7%). Discrepancies exist between payment disclosures made by authors and those published in the CMS Open Payments database. Although the percentage of articles with these discrepancies varies widely among the journals that were analyzed in this study, no trend was found when analyzing the number of discrepancies over the 3-year period.

Disclosures Undisclosed. · J Bone Joint Surg Am 2019
Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studyobservation of people
Participants3 465

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Interactions between cancer physicians and the pharmaceutical industry may create conflicts of interest that can adversely affect patient care. We aimed to survey cancer physicians regarding their attitudes toward and interactions with industry.

Results: There were 116 responses (94 complete). Almost half (n = 53 of 115, 46.1%) felt that there was a positive relationship between cancer physicians and industry. Most (n = 79 of 104, 76.0%) interacted with industry at least once a month, and 67.7% (n = 63 of 93) had received nonresearch payments from industry previously, with a median value of 2,000 Australian dollars over 1 year. Most respondents believed that interactions could influence prescribing while simultaneously denying influence on their own prescribing (n = 66 of 94, 70.2%). Those who judged general sales representative interactions (odds ratio [OR] 9.37 [95% CI, 1.05 to 83.41], P = .045) or clinician sponsorship (OR 3.22 [95% CI, 1.01 to 10.30], P = .049) to be more acceptable also met with sales representatives more frequently.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studyobservation of people
Participants116

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Canada is a laggard when it comes to transparency of transfers of value between the pharmaceutical industry and physicians and patient groups. In most high-income countries, transparency is mandated by the government or required for membership in industry associations.

Results: In most high-income countries, transparency is mandated by the government or required for membership in industry associations. Aside from one attempt by a previous Ontario Liberal government, provincial and federal governments have steered clear of this issue, and the role of Innovative Medicines Canada has been minimal. There is evidence showing that the receipt of payments by physicians and patient groups is associated with actions favourable to the pharmaceutical industry. Companies should have to disclose the payments that they make.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Conflicts of interest (COI) between physicians and for-profit companies have existed for centuries, but the last decade has dramatically increased their visibility through the Centers for Medicare and Medicaid Services' Open Payments database.

Results: The authors review the evidence linking industry interactions during medical training to favorable views of pharmaceutical marketing, greater propensity for continued industry engagement, and increased prescribing of promoted drugs and devices. The authors argue that medical schools and their governing bodies must implement and enforce meaningful COI policies, meeting at minimum the Association of American Medical Colleges' existing recommendations. The authors further recommend that the Liaison Committee on Medical Education require adherence to these policies for annual accreditation, that research curricula address the influence of funding sources on study design, and that the Open Payments database be integrated into medical training as a transparency tool. Strengthening COI education and policy is essential to ensure that the next generation of physicians learns in environments where patient-centered, evidence-based medicine guides decision-making.

Money for the studyuniversity or foundation · Arnold Ventures
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

What do orthomolecular medicine doctors write?

Orthomolecular Medicine News Service
„Sponsored research often focuses on topics that benefit industry, such as physical activity rather than processed foods(15). While some analyses found no significant difference in conclusions between industry and non-industry studies(16), others identified clear bias(17). Industry funding can influence study design, conduct, and publication(18). Historically, food companies have deliberately manipulated research to support their products and minimize perceived harms(17).”Sponsored research often focuses on topics that benefit industry, such as physical activity rather than processed foods(15). While some analyses found no significant difference in conclusions between industry and non-industry studies(16), others identified clear bias(17). Industry funding can influence study design, conduct, and publication(18). Historically, food companies have deliberately manipulated research to support their products and minimize perceived harms(17).
Orthomolecular Medicine News Service
„A systematic review found over half of guideline authors had industry ties, particularly in areas where pharmaceuticals dominate treatment(50,51). Many guideline panels lack formal processes for declaring conflicts of interest, with only 2 out of 44 reviewed guidelines containing specific disclosures(47). Undisclosed financial relationships were identified in 24% of authors who claimed no conflicts and 70% of guidelines(52). Impact on Care: Industry ties may influence guideline recommendations, potentially leading to overdiagnosis and overtreatment(53,54).”A systematic review found over half of guideline authors had industry ties, particularly in areas where pharmaceuticals dominate treatment(50,51). Many guideline panels lack formal processes for declaring conflicts of interest, with only 2 out of 44 reviewed guidelines containing specific disclosures(47). Undisclosed financial relationships were identified in 24% of authors who claimed no conflicts and 70% of guidelines(52). Impact on Care: Industry ties may influence guideline recommendations, potentially leading to overdiagnosis and overtreatment(53,54).
Orthomolecular Medicine News Service
„I attribute this to two factors: the pharmaceutical industry's great power and influence on medical practice, and the private insurance industry that provides accessibility of drugs to its clients by covering the cost---whatever it is. The uninformed patient is usually not aware of the actual cost covered by the insurer. This enables a for-profit insurance company to have full say of what expenses are covered, because it does not have to face challenges from those covered.”I attribute this to two factors: the pharmaceutical industry's great power and influence on medical practice, and the private insurance industry that provides accessibility of drugs to its clients by covering the cost---whatever it is. The uninformed patient is usually not aware of the actual cost covered by the insurer. This enables a for-profit insurance company to have full say of what expenses are covered, because it does not have to face challenges from those covered.

Sources (18)

Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.